Close

Mylan Labs to buy SMS Indian manufacturing unit

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Fluid Path Integrity: Ensuring Purity in Biomanufacturing

In the high-stakes arena of biomanufacturing, where tiny contaminants...

GMP Fluid Handling: Regulatory Compliance Explained

Fluid Handling in GMP Manufacturing: The Essence of Regulatory...

Single-Use Technologies in Biopharma Transform Manufacturing

The biopharmaceutical sector is being revolutionized by the demand...

Advances in Aseptic fluid transfer solutions

Sterility and Cross-Contamination: The Cornerstones of Modern Biopharma Manufacturing Biopharmaceutical...

Mylan Laboratories has agreed to purchase SMS Pharmaceuticals’ manufacturing unit-VI in Visakhapatnam, Andhra Pradesh, India, for a total sum of INR1.73bn ($33m).

The manufacturing unit was designed for the production of cancer medications and the active ingredients for cancer drugs.

SMS will use the proceeds to clear some of its existing debts, cut overhead costs, reports the Hindu Business Line.

In addition, SMS will use the finance to strengthen its existing production facilities and working capital.

SMS Pharma, which is involved in active pharmaceutical intermediaries manufacturing, said the legal process would take a couple of months.

 

Latest stories